Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)

Abstract Background To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene assay ODX) on treatment recommendations by Swiss multidisciplinary tumor boards (TB). Methods SAKK 26/10 is a multicenter, prospective cohort study of early breast cancer patients: Eligibility: R0-res...

Full description

Bibliographic Details
Main Authors: Bernhard C. Pestalozzi, Christoph Tausch, Konstantin J. Dedes, Christoph Rochlitz, Stefan Zimmermann, Roger von Moos, Ralph Winterhalder, Thomas Ruhstaller, Andreas Mueller, Katharina Buser, Markus Borner, Urban Novak, Catrina Uhlmann Nussbaum, Bettina Seifert, Martin Bigler, Vincent Bize, Simona Berardi Vilei, Christoph Rageth, Stefan Aebi, The Swiss Group for Clinical Cancer Research (SAKK)
Format: Article
Language:English
Published: BMC 2017-04-01
Series:BMC Cancer
Subjects:
ER-positive early breast cancer
Adjuvant treatment recommendation
Multigene expression profiling
Recurrence score
Oncotype DX
Online Access:http://link.springer.com/article/10.1186/s12885-017-3261-1

Internet

http://link.springer.com/article/10.1186/s12885-017-3261-1

Similar Items